Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.

Chairman: Arnold Levine, chairman, department of molecular biology, Princeton University Barry Bloom, Weinstock Professor and Howard Hughes Medical Institute (HHMI) investigator, department of microbiology and immunology, Albert Einstein College of Medicine, New York Rebecca Buckley, professor of pediatrics and immunology, Duke University Medical Center Charles Carpenter, chairman, Office of AIDS Research Advisory Committee; professor of medicine,Brown University School of Medicine Don

Bacteria that live in the digestive tracts of animals may influence the adaptive trajectories of their hosts.

Bacteria in the gut influence the production of antibodies and themselves secrete metabolites. In a pregnant woman, these compounds may influence immune development of her fetus.

Several labs have reported the formation of bacterial nanotubes under different, often contrasting conditions. What are these structures and why are they so hard to reproduce?

Meet some of the people featured in the June 2020 issue of The Scientist.

From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.

Ned Shaw US scientists have reason to feel both heady and scared. The federal government recently released unprecedented billions of dollars to fund bioterrorism research. Yet, the merits of this sudden shift in focus are being debated, and some worry that the money will be squandered or wasted. "I have been really very upset by the focus on bioterrorism," says Stanley Falkow, professor of microbiology and immunology and of medicine at Stanford University. "Everybody's talking about it, but th

The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.

The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.